Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

NCT07047885 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous T Cell Lymphoma

Interventions

DRUG: Ropeginterferon alfa-2b

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]